CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more
Market Cap & Net Worth: CanSino Biologics Inc (CASBF)
CanSino Biologics Inc (PINK:CASBF) has a market capitalization of $610.29 Million ($610.29 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #9879 globally and #4668 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CanSino Biologics Inc's stock price $4.60 by its total outstanding shares 132670900 (132.67 Million).
CanSino Biologics Inc Market Cap History: 2020 to 2025
CanSino Biologics Inc's market capitalization history from 2020 to 2025. Data shows change from $2.87 Billion to $610.29 Million (-8.66% CAGR).
CanSino Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CanSino Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
CanSino Biologics Inc's market cap is 0.63 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.87 Billion | $24.89 Million | -$396.64 Million | 115.25x | N/A |
| 2021 | $3.01 Billion | $4.30 Billion | $1.91 Billion | 0.70x | 1.57x |
| 2022 | $1.11 Billion | $1.03 Billion | -$909.43 Million | 1.08x | N/A |
| 2023 | $391.64 Million | $345.18 Million | -$1.48 Billion | 1.13x | N/A |
| 2024 | $517.42 Million | $824.88 Million | -$378.88 Million | 0.63x | N/A |
Competitor Companies of CASBF by Market Capitalization
Companies near CanSino Biologics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to CanSino Biologics Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
CanSino Biologics Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, CanSino Biologics Inc's market cap moved from $2.87 Billion to $ 610.29 Million, with a yearly change of -8.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $610.29 Million | +17.95% |
| 2024 | $517.42 Million | +32.11% |
| 2023 | $391.64 Million | -64.73% |
| 2022 | $1.11 Billion | -63.14% |
| 2021 | $3.01 Billion | +5.02% |
| 2020 | $2.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CanSino Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $610.29 Million USD |
| MoneyControl | $610.29 Million USD |
| MarketWatch | $610.29 Million USD |
| marketcap.company | $610.29 Million USD |
| Reuters | $610.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.